Vanda submits BLA to FDA for Imsidolimab to treat Generalized Pustular Psoriasis. Nasdaq: VNDA.
On December 15, 2025, Vanda Pharmaceuticals Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for imsidolimab, an innovative IgG4 IL-36 receptor antagonist designed to address generalized [specific condition]. Vanda, listed as VNDA on Nasdaq, made this significant move towards potential FDA approval for imsidolimab.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments